chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Diarrhoea, Gastrointestinal disorder, Nausea, Pyrexia
Clinical narrative: Fever; Chills; diarrhea; Nausea; GI issues; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the arm right on 04Apr2021 at 19:00 (at the age of 58-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history and was reported that the patient never had GI issues or problems with her bowel movements. The patient's concomitant medication included unspecified over-the-counter medications for cold within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER8735) via an unspecified route of administration in the right arm on an unknown date in Mar2021 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. On 04Apr2021 at 19:00, the patient experienced fever, chills, nausea, diarrhea and GI issues. The clinical course was reported as follows: the patient had a normal reaction for 2 days, fever, chills. The patient also had a lot of nausea and diarrhea. The diarrhea lasted for a week and the nausea lasted for one and half months. At the time of the report, the patient still had GI issues 6 weeks out. The events did not result in doctor or other healthcare professional office/clinic visits, and the emergency room/department or urgent care. Therapeutic measures were taken as a result of nausea included treatment with emetrol. The clinical outcome of the events fever and chills was resolved on 06Apr2021, after the duration of 2 days. The clinical outcome of the event diarrhea resolved on 11Apr2021, after the duration of a week. The clinical outcome of the event nausea was recovered on an unknown date in May2021, after the duration of one and a half months. The clinical outcome of the event GI issues was not recovered at the time of the event.  No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Breast pain, Pleuritic pain
Clinical narrative: Severe pain in left breast; Sharp pain, like pleuritic pain, especially on inhalation, much worse than after dose 1; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the arm left on 08Apr2021 at 13:00 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. The patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8736) via an unspecified route of administration in the arm left on 29Apr2021 at 12:00 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. Medical history included glaucoma. Concomitant medications included latanoprost (MANUFACTURER UNKNOWN) from unknown date taken for glaucoma. The patient was allergic to ampicillin (MANUFACTURER UNKNOWN). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Apr2021, after first dose of vaccine, the patient experienced severe pain in left breast, sharp, like pleuritic pain, especially on inhalation. On 29Apr2021 at 21:00, after second dose, the patient experienced severe pain in left breast, sharp, like pleuritic pain, especially on inhalation, much worse than after first dose. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the events which included treatment with ADVIL for pain, taken for 4- 5 days after just to breathe. The clinical outcome of the events severe pain in left breast, sharp, like pleuritic pain, especially on inhalation was unknown while that of the events severe pain in left breast, sharp, like pleuritic pain, especially on inhalation was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Breast pain, Pleuritic pain
Clinical narrative: Left breast pain; Sharp pain, like pleuritic pain, especially on inhalation; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 08Apr2021 at 13:00 (at the age of 59-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient's concomitant medication included latanoprost (glaucoma eye drops, MANUFACTURER UNKNOWN) for an unknown indication since an unknown date and unknown if ongoing. The patient previously took ampicillin (MANUFACTURER UNKNOWN) on an unknown date and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Apr2021 at 20:00, the patient experienced left breast pain and sharp pain, like pleuritic pain, especially on inhalation. The patient ruled out pulmonary embolism (PE). The events resulted in emergency room/department or urgent care. Therapeutic measures were taken as a result of adverse events which included treatment with unspecified medications. The clinical outcome of the events left breast pain and sharp pain, like pleuritic pain, especially on inhalation was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Sex: M
Vaccine: COVID19
Symptoms: Epistaxis
Clinical narrative: nose bleeds; This is a spontaneous report from a contactable consumer. A male patient of unknown age received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 14May2021 as a single dose for COVID-19 immunisation. It was unknown, whether the patient had any other medical history.  It was unknown, whether the patient had received any concomitant medication within two weeks of vaccination.  It was unknown, whether the patient had any allergy to medication, food or other products.  Prior to vaccination,  It was unknown, whether the patient was diagnosed with COVID-19. Since the vaccination, It was unknown, whether the patient had been tested for COVID-19. It was unknown, whether the patient receive any other vaccines within 4 weeks prior to the COVID vaccine. On 15May2021, patient experienced a nose one bleed one day after receiving his first Pfizer covid vaccination during a boy scout outing. Patient reported that nose bleeds are common for him at this time of year. The patient received treatment for the reported event which included compression of the nose. The adverse event did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The clinical outcome of the event nose bleeds was recovered on unknown date in May2021.    No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, Cough, Dysgeusia, Oropharyngeal pain
Clinical narrative: I have been coughing all day. I did not have this side-effect on any previous days, just this 3rd day so far.; It's day 3 and the taste has gone away.; Starting the day after injection, in the morning, my tongue tasted like metal for 2 days (food and drink tasted normal- except salt tasted sweeter).; however, now my throat is unbearably sore; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ew0177) via an unspecified route of administration on 11May2021 at 18:00 as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not receive any medication within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ew0162) via an unspecified route of administration on 18Apr2021 as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12May2021 at 11:00, a day after vaccination. In the morning the patient experienced like tongue tasted like metal for two days (food and drink tasted normal- except salt tasted sweeter). On 15May2021, the taste had gone away; however, the throat was unbearably sore. On 15May2021, the patient coughed all day. The patient did not have this side-effect on any previous days, but just on the third day after vaccination. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events tongue tasted like metal, sore throat and coughing were all recovering at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Electric shock sensation
Clinical narrative: I had SSRI withdrawal brain zaps; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the arm left on 05May2021 at 15:00 (at the age of 43-year-old) as a single dose for COVID-19 immunisation. Medical history included depression, colectomy (two colon resection) and total abdominal hysterectomy with bilateral salpingo-oophorectomy. Concomitant medications included citalopram (MANUFACTURER UNKNOWN), cetirizine hydrochloride (ZYRTEC), pantoprazole (MANUFACTURER UNKNOWN) ,loperamide hydrochloride (IMODIUM) and amfetamine aspartate, amfetamine sulfate, dexamfetamine saccharate, dexamfetamine sulfate (ADDERALL) from unknown date for unknown indication. It was reported that the patient had no allergies to medications, food, or other products.  The patient did not receive any vaccination within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 05May2021 at 17:00, the patient experienced had SSRI withdrawal brain zaps. The patient reported that after the 2nd dose, patient had SSRI withdrawal brain zaps, but patient had not missed or taken the citalopram late, that occurred for about 30 hours total, and began within about two hours of the vaccination. The patient did not receive any treatment for the events. The events do not resulted in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event SSRI withdrawal brain zaps was on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Migraine, Pyrexia, Vomiting
Clinical narrative: Migraine; High fever over 103, over 102 with meds; Joint pain; Vomiting; This is a spontaneous report from a non-contactable consumer, the patient. A 40-year-old, non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 14May2021 at 08:45 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. Medical history included thrombocytopenia. The patient had no known allergies to medications, food or other products. Concomitant medications included multivitamin (MANUFACTURER UNKNOWN), magnesium (MANUFACTURER UNKNOWN) and acetylsalicylic acid (BABY ASPIRIN) all for unknown indications from an unknown date. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14May2021 at 21:00, the patient experienced migraine, high fever over 103, over 102 with meds, joint pain and vomiting. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. On 14May2021 patient underwent lab tests which include body temperature and the result was over 103( unspecified units) and over 102 (unspecified units). Therapeutic measures were taken as a result of the event high fever over 103, over 102 with meds which included treatment with unspecified medications. No therapeutic measures were taken as a result of events migraine, joint pain and vomiting. The clinical outcome of the events migraine, high fever over 103, over 102 with meds, joint pain and vomiting were not recovered at the time of this report.    No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 12.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Cough, Feeling hot, Nasal congestion, Secretion discharge
Clinical narrative: stuffed nose; cough; no fever but chills; feels warm; mucus; This is a spontaneous report from a contactable consumer. A 12-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via intramuscular route of administration in the left arm on 14May2021 at 14:00 (at the age of 12-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Patient did not receive any medications within two weeks. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15May2021, the patient experienced stuffed nose, cough, mucus, no fever but chills. feels warm, but no measurable fever. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events stuffed nose, cough, mucus, no fever but chills. feels warm, but no measurable fever was unknown.   No follow-up attempts are needed. No further information is expected.
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Lymph node pain, Lymphadenopathy, Menstruation irregular
Clinical narrative: Awfully painful swollen lymph nodes in neck and underarm on the side of my body I received the vaccine; Period become irregular; Awfully painful swollen lymph nodes in neck and underarm on the side of my body I received the vaccine; This is a spontaneous report from a non-contactable consumer, the patient. A 17-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on an unknown date in Apr2021 (at the age of 17-years-old) and a second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173), via an unspecified route of administration in the left arm on an unknown date in May2021 (at the age of 17-years-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On an unknown date in 2021, the patient experienced awfully painful swollen lymph nodes in neck and underarm on the side of her body she received the vaccine and the vaccine also caused the period to become irregular. It was reported that the patient was fairly certain that's temporary. The clinical outcome of the events awfully painful swollen lymph nodes in neck and underarm on the side of her body she received the vaccine and period become irregular were unknown at the time of reporting.   No follow-up attempts are possible. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, Menstrual disorder, Polymenorrhoea
Clinical narrative: Abnormal menstrual cycle-Early onset of menstrual cycle after the shot, 2 periods within one month; Abnormal menstrual cycle-Early onset of menstrual cycle after the shot, 2 periods within one month; Dose 1: 14Apr2021 and Dose 2: 28Apr2021; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 28Apr2021 (at the age of 35-year-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. Concomitant medications included vitamins (MANUFACTURER UNKNOWN) from an unknown date for an unknown indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 14Apr2021 (at the age of 35-year-old) as a single dose for COVID-19 immunisation and took codeine on an unknown date for an unspecified indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02May2021, the patient experienced abnormal menstrual cycle, early onset of menstrual cycle after the shot, which resulted in 2 periods within one month. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events abnormal menstrual cycle and early onset of menstrual cycle after the shot, 2 periods within one month were unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Feeling hot, Flushing, Nausea, Pruritus
Clinical narrative: Nausea; Felt hot; Face turned flush; Itched all over but no rash; Tight chest; This is a spontaneous report from a non-contactable consumer, the patient. A 48-year-old, non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 25Apr2021 at 14:30 (at the age of 48-year-old) as a single dose for COVID-19 immunisation. Medical history included allergies, asthma, penicillin allergy and Band-Aid allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medication within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously took morphine and Demerol and experienced allergy to it. On 25Apr2021 at 14:30, the patient immediately felt hot, face turned flush, itched all over but no rash and tight chest. All symptoms only lasted 30 mins, except tight chest. The event tight chest lasted for two days. Other adverse reactions were consistent with known side effects and lasted for four days. After recuperating and feeling well for 6 days, on day 10 after dose 1 (on 05May2021), the patient suddenly experienced nausea for a duration of two days. Nausea was not a symptom the patient had previously. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of events felt hot, face turned flush and itched all over but no rash was recovered on 25Apr2021 at 15:00, tight chest was recovered on 27Apr2021 and nausea was recovered on 07May2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Hot flush
Clinical narrative: hot flashes; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 22Apr2021 at 09:30 (at the age of 56-years-old), as a single dose for COVID-19 immunisation. Medical history included anxiety. The patient did not have a history of allergies to any food or medications or other products. The patient received unspecified medications within two weeks prior to vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 01Apr2021 at 10:30 (at the age of 56-year-old), as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 23Apr2021, the patient experienced hot flashes. No therapeutic measures were taken for the events. The clinical outcome of the event hot flashes was unknown at the time of report.   No follow up attempts are needed; information about lot/batch number cannot be obtained. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Computerised tomogram, Diplopia, Ear, nose and throat examination, Glycosylated haemoglobin, SARS-CoV-2 test
Clinical narrative: developed and retained diplopia; This is a spontaneous report received from a contactable consumer (patient) via Regulatory Authority. This non-pregnant 42-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; lot number EN6201) via an unspecified route of administration in the right arm on 07Feb2021 (at 42-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had not received any other vaccines in the four weeks prior to the COVID vaccine. The patient took unspecified concomitant medications within 2 weeks of the COVID-19 vaccine. The patient previously received sulfamethoxazole, trimethoprim (BACTRIM) from an unknown date for an unknown indication and experienced allergy. On 08Feb2021 the patient developed and retained diplopia; further reporting increased intensity after the second shot. The patient reported it had been going on for 14, almost 15, weeks. The event required an ophthalmology doctor's office visit and was treated. Lab tests included a computerised tomogram (CAT scan); ear, nose, and throat (ENT) scope, and A1C blood tests, all of which were completed on unknown dates with unknown results. The patient received the second dose of BNT162B2 on 28Feb2021. The clinical outcome of diplopia was not recovered. Since vaccination the patient was tested for COVID-19 on 05May2021 via nasal swab which was negative.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Chest pain, Fatigue, Headache, Lymphadenopathy
Clinical narrative: Acute chest pains in the upper right of chest; Lymph node swelling; Fatigue; Headache; This is a spontaneous report from a non-contactable consumer, the patient. A 42-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0182) via an unspecified route of administration in the left arm on 14May2021 at 16:00 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included none. The patient had no known allergies to medications, food or other products. Concomitant medication included ibuprofen (ADVIL); taken for unknown indication from 10May2021 (4 days prior to second dose). The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8736) via an unspecified route of administration in the left  arm on 23Apr2021 at 15:00 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15May2021 at 11:00, the patient experienced unusual side effects acute chest pains in the upper right of chest that occurred sporadically and lymph node swelling. Usual side effects also included fatigue and headache. The events resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the events. The clinical outcome of the events acute chest pains in the upper right of chest, lymph node swelling, fatigue and headache was not resolved at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 47.0
Sex: M
Vaccine: COVID19
Symptoms: Lymphadenopathy, SARS-CoV-2 test
Clinical narrative: Swollen lymph node in left arm; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0183) via an unspecified route of administration in the left arm on 13May2021 at 15:30 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies to medications, food or other products. The patient did not receive any other medications within two weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 22Apr2021 at 15:30 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14May2021 at 16:00, the patient experienced swollen lymph node in left arm (the arm where shot was administered). The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. On an unknown date in 2021, the patient underwent nasal swab test and the result was negative. The clinical outcome of the event swollen lymph node in left arm was not recovered at the time of the report.   No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Vaccination site pain
Clinical narrative: Injection site pain; severe headache; fatigue; This is a spontaneous report from a non-contactable consumer, the patient. A 47-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the left arm on an unknown date in 2021 as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On an unknown date in 2021, the patient experienced injection site pain, severe headache and fatigue. The clinical outcome of the events injection site pain, severe headache and fatigue were recovered on an unknown date in 2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 14.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Vaccination site pain
Clinical narrative: Mild headache; Mild fatigue; Mild injection site pain; This is a spontaneous report from a non-contactable consumer, the patient. A 14-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 13May2021 at 15:15 (at the age of 14-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications were not reported. On 13May2021 at 15:15, the patient experienced mild injection site pain. On 14May2021, the patient experienced mild headache and mild fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event mild injection site pain, mild headache, and mild fatigue were recovered on an unknown date in May2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure increased, Heart rate increased, Palpitations
Clinical narrative: Elevated blood pressure; heart palpitations; increased heart rate.; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 22Apr2021 at 10:00 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. The patient received other medications within two weeks of vaccination, names unspecified. The patient previously took amoxicillin (MANAFACTURER UNKNOWN), Topiramate (MANAFACTURER UNKNOWN), Zithromax (Z-PACK) all from an unknown date for an unspecified indication and experienced drug allergy. The patient previously took first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in left arm on 25Mar2021 at 10:00 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Apr2021, the patient experienced elevated blood pressure, heart palpitations and increased heart rate. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events and included treatment with blood pressure medication, heart monitor. The clinical outcome of the events elevated blood pressure, heart palpitations and increased heart rate was not recovered.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Pyrexia
Clinical narrative: Fever cleared next day however slept the whole day on the second day due to headache and fatigue. Headache and fatigue still ongoing at the time of reporting (a week after receiving the 2nd shot); Fever cleared next day however slept the whole day on the second day due to headache and fatigue. Headache and fatigue still ongoing at the time of reporting (a week after receiving the 2nd shot); Fever started around 11PM on the day receiving my 2nd shot. Fever cleared next day however slept the whole day on the second day due to headache and fatigue; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 08May2021 at 09:45 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient received other medication within two weeks of vaccination which included birth control pill (unspecified). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Fever started around 23:00 on 08May2021, the day patient received her second shot. Fever cleared next day however she slept the whole day on 09May2021, the second day due to headache and fatigue. Headache and fatigue was still ongoing at the time of reporting (a week after receiving the second shot). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the event fever started around 23:00 was resolved with sequelae on the next day on 09May2021. The clinical outcome of the events slept the whole day the second day due to headache and fatigue, headache and fatigue was still ongoing at the time of reporting (a week after receiving the second shot) was not resolved at the time of report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Pain
Clinical narrative: Very slight acheyness starting around 11:00am the next morning and ending same day around 8pm.; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EW0179), via an unspecified route of administration in the right arm on 13May2021 at 15:00 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. The patient was allergic to amoxicillin (MANUFACTURER UNKNOWN). Concomitant medications included fluoxetine hydrochloride (PROZAC), amfetamine aspartate, amfetamine sulfate, dexamfetamine saccharate and dexamfetamine sulfate (ADDERALL), vitamin d nos (VITAMIN D) and electrolytes nos (MANUFACTURER UNKNOWN); all for unknown indications since unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EW0179), via an unspecified route of administration in the right arm on 22Apr2021 at 15:00 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14May2021 at 11:00, the patient experienced very slight acheyness starting around 11:00 the next morning and ending same day around 20:00.The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as the result of the reported adverse events. The clinical outcome of the event very slight acheyness was recovered on 14May2021.   No follow-up attempts are needed. No further information is expected.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Discomfort, Lymph node pain, Lymphadenopathy, Sleep disorder
Clinical narrative: Tender lymph node in left armpit; Uncomfortable; Disturb sleep; Swollen lymph node in left armpit; This is a spontaneous report from a non-contactable consumer, the patient. A 70-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0176) via an unspecified route of administration in the arm left on 12May2021 at 13:00 (at the age of 70-year-old) as a single dose for COVID-19 immunisation. Medical history included breast cancer (left breast) from 24 years, diverticulosis, IBS (irritable bowel syndrome), SIBO (small intestinal bacterial overgrowth), malabsorption, osteoporosis, kidney stones, sulfonamide allergy and allergy to GI-intolerant of garlic, onions, cruciferous veg's. Concomitant medications included VITAMIN D3 and vitamin k (MANUFACTURER UNKNOWN) started from an unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration in the arm left on 23Apr2021 at 13:00 as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. 30 hours post the injection, on 13May2021 at 19:00, the patient began with swollen, tender lymph node in left armpit, uncomfortable enough to disturb sleep that night. The patient was a breast cancer survivor (24 yrs). Cancer was also in left breast. Therapeutic measures were not taken as a result of these events. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event tender lymph node in left armpit, uncomfortable, disturb sleep and swollen lymph node in left armpit was not resolved and at 72 hours there was no change yet.   No follow-up attempts are possible. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Swelling face
Clinical narrative: Face swelling; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 16May2021 at 12:00 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. The patient medical history was reported as none. The patient had no allergies to food, medications or other products. The patient did not receive any other medications within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 18Apr2021 at 12:00 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 16May2021 at 19:00, the patient experienced the event face swelling. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. It was unknown whether any therapeutic measures were taken as a result of the event.  The clinical outcome of the event face swelling was not recovered at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Sex: F
Vaccine: COVID19
Symptoms: Feeling abnormal, Hypoaesthesia
Clinical narrative: numb arm; prickly feeling; This is a spontaneous report from a contactable consumer. This consumer reported for a female patient (neighbour). A female patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot number, expiration date not reported) via an unspecified route of administration on an unspecified date as dose 1, single for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The reporter stated that neighbour had prickly feeling and a numb arm after the first shot (on an unspecified date). The outcome of the events numb arm and prickly feeling was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 14.0
Sex: F
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: Long splotchy rash on the underside of both arms.; This is a spontaneous report from a contactable consumer, the patient. A 14-year-old non-pregnant female patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the right arm on 15May2021 at 12:00 (at the age of 14-years-old) as a single dose for COVID-19 immunisation. The patient had no known medical history. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 15May2021 at 13:00 the patient experienced long splotchy rash on the underside of both arms. The adverse event did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. No therapeutic measures were taken for the reported events. The clinical outcome of the event long splotchy rash on the underside of both arms was not recovered at the time of reporting.   No follow-up attempts are possible. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: Shingles; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0153) via an unspecified route of administration in the right arm on 21Apr2021 at 10:00 as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not receive any medication within two weeks of vaccination. The patient previously took amoxicillin and experienced allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 04May2021 at 12:00 the patient experienced Shingles. The event resulted in doctor or other healthcare professional office/clinic visits. Therapeutic measures were taken as a result of shingles included treatment with famciclovir 500mgtap, gabapentin 300mgcap. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event shingles was resolving at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 46.0
Sex: M
Vaccine: COVID19
Symptoms: Vision blurred
Clinical narrative: "Woke up this morning with blurred vision"; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EM9810) via an unspecified route of administration in the left arm on 14May2021 at 15:45 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. Medical history included none. The patient had no known allergies. The patient did not receive any medications within 2 weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: fN6207) via an unspecified route of administration in the left arm on 23Apr2021 at 15:30 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15May2021 at 08:15, the patient woke up this morning (the day after the vaccination) with blurred vision. The patient sometimes uses reading glasses to see smaller print but this was different. The patient could not see words on the TV clearly, that he usually had never had a problem reading and everything was blurred even with reading glasses. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the event. The clinical outcome of the event "woke up this morning with blurred vision" was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 23.0
Sex: M
Vaccine: COVID19
Symptoms: Epistaxis
Clinical narrative: Mild (4/10) nose bleed 5/14, within the bounds of being relatively normal. Severe/Worse (6/10) nose bleed 5/15, low viscosity/high flow rate. Blood flowed into the throat before out the nose; This is a spontaneous report from a contactable consumer, the patient. A 23-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN0153) via an unspecified route of administration in the left arm on 13May2021 at 19:45 (at the age of 23-year-old) as a single dose for COVID-19 immunisation. The patient's medical history included sport induced asthma, (3/10) no inhaler prescribed and allergy to erythromycin since an unspecified date. The patient's concomitant medications were not reported. The patient previously received erythromycin (MANUFACTURER UNKNOWN) and experienced drug allergy on an unknown date. The patient also received previously the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN0153) via an unspecified route of administration in the left arm on 22Apr2021 at 19:45 (at the age of 23-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14May2021 at 19:00, the patient experienced mild (4/10) (unit unspecified) nose bleed 5/14, within the bounds of being relatively normal and severe/worse (6/10) nose bleed 5/15, low viscosity/high flow rate. Blood flowed into the throat before out the nose. Both times nose bleed lasted under 2- 3min. The patient was advised via phone call from nurse and physician. Therapeutic measures were taken as a result of adverse event which included treatment with unspecified medications. The clinical outcome of the event mild (4/10) nose bleed 5/14, within the bounds of being relatively normal and severe/worse (6/10) nose bleed 5/15, low viscosity/high flow rate. Blood flowed into the throat before out the nose was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.